Novartis: confirms it annual forecasts

(CercleFinance.com) - Novartis has communicated results over and above expectations this morning, and has confirmed its forecasts for the financial year as a whole.


The Swiss pharma giant has reported a turnover of 13.1 billion dollars for the 2nd quarter of its 2018 financial year, i.e. +7% in this currency and +5% at constant exchange rates. Sales of drugs Cosentyx, Entresto and oncology products have notably contributed to this increase.

Core operational results were up 7% to 3.5 billion dollars (+9% excluding currency effects), and net profits up 3% to 3 billion (+5%), or 1.29 dollars per share.

The Basel-based Group has also confirmed its forecasts for the 2018 financial year: although those for sales of Sandoz have been revised downwards, those for sales of Alcon have been revised upwards.

Copyright (c) 2018 CercleFinance.com. All rights reserved.